The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients

Miodońska, Martyna; Bogacz, Agnieszka; Mućka, Szymon; Bożek, Andrzej

doi:10.3390/medicina57060521

Cited by 10 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patients with severe atopic dermatitis who were receiving immunosuppressive therapy had milder exacerbations. 16 …”

Section: Resultsmentioning

confidence: 99%

“…Another study assessed 21 adults with atopic dermatitis who had also been infected with COVID‐19 and found out that 43% of these patients experienced disease exacerbation that did not require systemic intervention. The patients with severe atopic dermatitis who were receiving immunosuppressive therapy had milder exacerbations 16 …”

Section: Resultsmentioning

confidence: 99%

“…The patients with severe atopic dermatitis who were receiving immunosuppressive therapy had milder exacerbations. 16 In a questionnaire-based survey in Italy, the investigators contacted 475 patients previously diagnosed with alopecia areata (AA) to follow up on their conditions after COVID-19. 42.5% of their participants who had been infected with SARS-CoV2 experienced a relapse that occurred about 2 months after COVID-19 (median of 2.14 months).…”

mentioning

confidence: 99%

See 2 more Smart Citations

COVID‐19 and exacerbation of dermatological diseases: A review of the available literature

Khashayar

Patil

Goldust

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Since the emergence of the new coronavirus disease 19 (COVID‐19) pandemic, there has been a concern for the patients with chronic autoimmune diseases including dermatological conditions over the potential exacerbation of these underlying conditions after infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV2). We performed a systematic review to evaluate presentations, postinfection change in the manifestation, diagnosis, and management of flare‐ups of underlying dermatologic disease in patients with COVID‐19. A total of 17 articles were recovered reporting on flare‐ups of dermatological disease including pemphigus vulgaris, psoriasis, subacute cutaneous lupus erythematosus, acrodermatitis continua of Hallopeau, systemic sclerosis sine scleroderma, and Sézary syndrome (SS). Out of these, psoriasis and alopecia areata were the most common conditions. However, most cases of psoriasis could have been attributed to either antimalarial agents that were initially used for the treatment of COVID‐19 or discontinuation of treatment following SARS‐CoV2 infection.

show abstract

“…The patients with severe atopic dermatitis who were receiving immunosuppressive therapy had milder exacerbations. 16 …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

COVID‐19 and exacerbation of dermatological diseases: A review of the available literature

Khashayar

Patil

Goldust

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…This is a significant limitation of this study. However, a similar observational study in patients with atopic dermatitis and immunosuppressive therapy also found no effect on the severity of COVID-19 [ 18 ]. The possible negative effects of this type of therapy should be emphasized.…”

Section: Discussionmentioning

confidence: 99%

Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background and objectives: Biological treatment is an important and effective therapy for psoriasis. During the COVID-19 pandemic, it remains unclear whether this type of therapy affects the course of SARS-CoV-2 infection. The aim of the study was to observe patients with psoriasis undergoing biological or other systemic treatment in relation to the impact of SARS-CoV-2 infection on the course of psoriasis and the COVID-19 disease itself. Materials and methods: A one-year observational study included 57 patients with diagnosed psoriasis who qualified for biological treatment and a group of 68 similar patients who were administered a different systemic treatment. Patients were analyzed monthly for psoriasis (including Psoriasis Area Severity Index (PASI) assessment) and constantly for SARS-CoV-2 infection (telephone contact). Cases of COVID-19 were confirmed by Polymerase Chain Reaction (PCR) at the study center. Results: SARS-CoV-2 infection was confirmed by a positive Real Time Polymerase Chain Reaction (RT-PCR) test in eight patients (14.0%) with psoriasis on biological therapy. None of the cases in this group required hospitalization for COVID-19. Similar data were obtained in the control group. Specifically, 11 (16%) patients were confirmed to be infected with SARS-CoV-2. These results were statistically comparable (p > 0.05). In the group of patients undergoing biological treatment, six (75%) of eight patients developed an exacerbation of psoriasis during SARS-CoV-2 infection, and similar results were noted in the control group, with eight (72%) patients experiencing an exacerbation of psoriasis. Conclusions: Patients with psoriasis who were administered biological treatment or other systemic therapy may experience a mild course of SARS-CoV-2 infection but might also experience a temporary exacerbation of skin lesions.

show abstract

“…The systemic conditions may be accompanied by skin lesions in which the innate immune system is involved [34,35]. Associated immune-mediated skin diseases, such as psoriasis, atopic dermatitis, and suppurative hidradenitis, have been reported [36,37].…”

Section: Skin Involvementmentioning

confidence: 99%

COVID-19 and Its Repercussions on Oral Health: A Review

et al. 2021

View full text Add to dashboard Cite

In 2019, a new type of coronavirus, SARS-CoV-2, the causing agent of COVID-19, was first detected in Wuhan, China. On 11 March 2020, the World Health Organization declared a pandemic. The manifestations of COVID-19 are mostly age-dependent and potentially more severe in cases with involved co-morbidities. The gravity of the symptoms depends on the clinical stage of the infection. The most common symptoms include runny nose and nasal congestion, anosmia, dysgeusia or hypogeusia, diarrhea, nausea/vomiting, respiratory distress, fatigue, ocular symptoms, diarrhea, vomiting, and abdominal pain. These systemic conditions are often accompanied by skin and mucosal lesions. Oral lesions reported in patients with COVID-19 include: herpex simplex, candidiasis, geographic tongue, aphthous-like ulcers, hemorrhagic ulcerations, necrotic ulcerations, white hairy tongue, reddish macules, erythematous surfaces, petechiae, and pustular enanthema. It is still unclear if these manifestations are a direct result of the viral infection, a consequence of systemic deterioration, or adverse reactions to treatments. Poor oral hygiene in hospitalized or quarantined COVID-19 patients should also be considered as an aggravating condition. This narrative review is focused on presenting the most relevant data from the literature regarding oral manifestations related to SARS-CoV-2, as well as the challenges faced by the dental system during this pandemic. A routine intraoral examination is recommended in COVID-19 patients, either suspected or confirmed, as, in certain cases, oral manifestations represent a sign of severe infection or even of a life-threatening condition. It is our belief that extensive knowledge of all possible manifestations, including oral lesions, in cases of COVID-19 is of great importance in the present uncertain context, including new, currently emerging viral variants with unknown future impact.

show abstract

The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients

Cited by 10 publications

References 31 publications

COVID‐19 and exacerbation of dermatological diseases: A review of the available literature

COVID‐19 and exacerbation of dermatological diseases: A review of the available literature

Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs

COVID-19 and Its Repercussions on Oral Health: A Review

Contact Info

Product

Resources

About